Chronic Bronchitis Treatment Guidelines

Traditional Chronic Bronchitis Treatment Guidelines Are Limited to Relieving Patients’ Symptoms

Unlike traditional chronic bronchitis treatment guidelines, which focus only on alleviating associated symptoms, the Lung Institute’s cellular therapy procedures aim to slow the progression of the disease itself. Chronic bronchitis, which is characterized by inflammation within the lungs’ air passages, causes various symptoms including excess mucus production, coughing and difficulty breathing. Chronic bronchitis can be distinguished from acute bronchitis because it lasts for at least three months and reoccurs at least once per year, for at least two consecutive years. Although the symptoms associated with chronic bronchitis persist for at least three months at a time, infections or environmental irritants may cause them to worsen at certain points during that period.

Some of the methods traditionally used to treat chronic bronchitis include the following:

  • Bronchodilators
  • Corticosteroids
  • Pulmonary rehabilitation
  • Supplemental oxygen therapy

It’s important to note, however, that these traditional treatment methods only address the symptoms of chronic bronchitis. The cellular therapy procedures offered at the Lung Institute are different, in that they address the root of the problem and can help slow the progression of the disease itself. Our three-step treatment process is minimally invasive and can be performed on an outpatient basis over the course of two days. First, we remove a small sample of a patient’s blood or bone marrow. Second, we take the sample to our onsite lab, where we separate out the cells. Third, we intravenously reintroduce the concentrated cells into the patient’s bloodstream. Because cells have the ability to regenerate as other types of bodily tissue, they can promote natural healing and help reduce inflammation.

If you would like more information on how cellular therapy can be used to supplement traditional chronic bronchitis treatment guidelines, please contact the Lung Institute at (800) 729-3065.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.